

Supplementary Information for:

Reaction between a haemoglobin model compound and hydrogen sulfide in aqueous solution

Kenji Watanabe,^{a,*} Toshikane Suzuki,^b Hiroaki Kitagishi,^b Koji Kano^{b,*}

^a *Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan. E-mail: kwatanabe@phar.kyushu-u.ac.jp*

^b *Department of Molecular Chemistry and Biochemistry, Faculty of Science and Engineering, Doshisha University, Kyotanabe, Kyoto 610-0321, Japan. E-mail: kojikano1223@gmail.com*

Instruments.

UV-Vis absorption spectra were measured using a Shimadzu UV-2400 spectrophotometer. Electron paramagnetic resonance (EPR) spectra were recorded on a JES-TE200 ESR system (JEOL Ltd., Tokyo, Japan). F-52 pH meter (Horiba Ltd., Kyoto, Japan) was used for pH measurements.

Materials.

Water was distilled by Yamato Auto Still Glass Model WG250, and further purified by Millipore Simpact 1. NaSH (100 %) was purchased from Strem Chem. Inc. and was used as received. CO (99.999 %), O₂ (99.999 %) and argon (99.999 %) gasses were purchased from Sumitomo Seika Chemicals. HemoCD3 was prepared as described in a previous study.¹ All other reagents were purchased and used as received.

Preparation of NaSH solution.

A solution of NaSH was freshly prepared in the globe box under argon atmosphere. Deoxidized aqueous phosphate buffered solutions were prepared by three freeze-pump thaw cycles and brought into the globe box. The concentration of the NaSH aqueous solution was determined by iodometric titration:² 10 mL of aqueous NaSH solution was combined with 5 mL of aqueous I₂ solution (0.05 M) containing appropriate amount of KI (0.1 M) and starch (solution A). Then, aqueous Na₂S₂O₃ solution (0.1 M) was titrated for the solution A. The point where the blue solution turned colourless was considered to be the end point of the titration.

Redox reaction between I₂ and I⁻ is shown in Eq 1.



Equilibrium between I₂ and I₃⁻ in the presence of KI is shown in Eq 2.



NaSH and Na₂S₂O₃ reduce I₂ (Eq 3 and 4).



Therefore, the initial concentration of NaSH ([NaSH]₀) in solution A is expressed as Eq 5. [I₂]₀ and [I₃⁻]₀ represent the initial concentrations of I₂ and I₃⁻, respectively, in solution A. [I₂] and [I₃⁻] represent the final concentration of I₂ and I₃⁻, respectively, in solution A, where NaSH is fully consumed.

$$[\text{NaSH}]_0 = ([\text{I}_2]_0 + [\text{I}_3^-]_0) - ([\text{I}_2] + [\text{I}_3^-]) \quad \text{Eq 5}$$

[I₂] and [I₃⁻] are expressed as shown in Eq 6,

$$[\text{I}_2] + [\text{I}_3^-] = x \cdot [\text{Na}_2\text{S}_2\text{O}_3] / 2v \quad \text{Eq 6}$$




where [Na₂S₂O₃], x, and v represent the concentration of the aqueous Na₂S₂O₃ solution, titrated volume of Na₂S₂O₃ solution, and the volume of solution A.

Eqs 5 and 6 are combined leading to Eq 7, which gives the [NaSH]₀ of the solution A.

$$[\text{NaSH}]_0 = ([\text{I}_2]_0 + [\text{I}_3^-]_0) - x \cdot [\text{Na}_2\text{S}_2\text{O}_3] / 2v \quad \text{Eq 7}$$

1. K. Watanabe, H. Kitagishi and K. Kano, *Angew. Chem. Int. Ed.*, 2013, **52**, 6894-6897.
2. Hujii, H. *Bunsekikagaku*, 1972, **21**, 1574-1579.

Structures of Py3OCD, Fe(III)TPPS and met-hemoCD3.






Fig. S1 EPR spectra of the Fe(III)TPPS/(TMe- β -CD)₂ complex (5.0×10^{-4} M) in the presence of various amounts of NaSH (0 eq. (A); 1 eq. (B); 2 eq. (C); 3 eq. (D)) in phosphate buffer at pH 6 and 77 K.




Fig. S2 UV-Vis absorption spectral changes of met-hemoCD3 (5×10^{-6} M) upon addition of NaSH in phosphate buffer at pH 6 and 25 °C.




Fig. S3 Progressive absorption spectral changes during spontaneous reduction of (SH⁻)-met-hemoCD3 ([met-hemoCD3 = 5.0×10^{-6} M]; [NaSH] = 5.0×10^{-5} M) to Fe(II)-hemoCD3 in deoxidised phosphate buffer at pH 7 and 25 °C. The spectra were recorded at 5-min intervals.




Fig. S4 UV-Vis absorption spectral changes of met-hemoCD3 (5×10^{-6} M) upon addition of NaSH (0-100 eq.) in phosphate buffer at pH 6 and 25 °C under CO atmosphere.